Document Detail

Managing adverse effects and complications in completing treatment for hepatitis C virus infection.
MedLine Citation:
PMID:  23154251     Owner:  NLM     Status:  In-Data-Review    
The addition of direct-acting antivirals (DAAs) to hepatitis C virus (HCV) treatment regimens has made treatment more effective and patient management more complex. Shepherding patients through a full course of HCV therapy requires motivation and involvement on the part of the patient and the physician. Indeed, physician inexperience and lack of confidence in guiding patients through the challenges of treatment appears to be a primary reason for early discontinuation of therapy. Among the many complications of HCV treatment that must be managed efficiently and effectively are depression and other psychiatric disorders; hematologic abnormalities including DAA- and ribavirin-associated anemia and peginterferon alfa-associated neutropenia and thrombocytopenia; rash and drug eruptions, including telaprevir-associated rash; and weight loss. Practical considerations in management of these common complications are offered. This article summarizes a presentation by Kenneth E. Sherman, MD, PhD, at the IAS-USA live continuing medical education course held in New York in June 2012.
Kenneth E Sherman
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Topics in antiviral medicine     Volume:  20     ISSN:  2161-5853     ISO Abbreviation:  Top Antivir Med     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-11-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101560274     Medline TA:  Top Antivir Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  125-8     Citation Subset:  IM    
University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Carbon Dioxide Laser Treatment of Epidermal Nevi: Response and Long-Term Follow-Up.
Next Document:  Cardiovascular risk and dyslipidemia management in HIV-infected patients.